AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AMPLIA THERAPEUTICS LTD

0.120

-0.010-7.69%

Volume:521.23K

Turnover:65.57K

Market Cap:61.57M

PE:-7.32

High:0.130

Open:0.130

Low:0.120

Close:0.130

52wk High:0.275

52wk Low:0.100

Shares:513.07M

Float Shares:351.32M

Volume Ratio:1.29

T/O Rate:0.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.016

EPS(LYR):-0.016

ROE:-25.48%

ROA:-16.29%

PB:1.56

PE(LYR):-7.32

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth

Simply Wall St.

Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study

Amplia Signs Collaboration Agreement with Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12c Inhibitor, Olomorasib, in Non-Small Cell Lung Cancer

THOMSON REUTERS

Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/ATX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ATX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","market":"AU","secType":"STK","nameCN":"AMPLIA THERAPEUTICS LTD","latestPrice":0.12,"timestamp":1789020720000,"preClose":0.13,"halted":0,"volume":521229,"delay":0,"changeRate":-0.07692307692307698,"nameEN":"AMPLIA THERAPEUTICS LTD","floatShares":351321835,"shares":513071629,"eps":-0.0164,"marketStatus":"Closed","change":-0.01,"latestTime":"09-10 16:12:00 AEST","open":0.13,"high":0.13,"low":0.12,"amount":65570,"amplitude":0.076923,"askPrice":0.135,"askSize":738149,"bidPrice":0.12,"bidSize":133466,"shortable":3,"etf":0,"ttmEps":-0.0164,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.13,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.294473,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"ATX.AU","preClose":0.13,"auctionPrice":0.12,"auctionVolume":15810,"auctionTime":1789020590603,"referencePrice":0.12,"referenceTime":1789022520291,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020590603}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ATX.AU\",,,,,undefined,":{"symbol":"ATX.AU","floatShares":351321835,"roa":"-16.29%","roe":"-25.48%","lyrEps":-0.0164,"volumeRatio":1.294473,"shares":513071629,"dividePrice":0,"high":0.13,"amplitude":0.076923,"preClose":0.13,"low":0.12,"week52Low":0.1,"pbRate":"1.56","psRate":"12.85","week52High":0.275,"institutionHeld":0,"latestPrice":0.12,"committee":-0.69375,"eps":-0.0164,"divideRate":0,"volume":521229,"delay":0,"ttmEps":-0.0164,"open":0.13,"prevYearClose":0.15,"prevWeekClose":0.13,"prevMonthClose":0.135,"prevQuarterClose":0.145,"fiveDayClose":0.135,"twentyDayClose":0.145,"sixtyDayClose":0.12,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATX.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-04-18","symbol":"ATX.AU","defaultRemindTime":1713398400000,"type":"split","dateTimestamp":1713362400000,"forFactor":971896,"toFactor":1000000,"ratio":0.971896}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATX.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664817028","title":"Companies Like Amplia Therapeutics (ASX:ATX) Are In A Position To Invest In Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2664817028","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664817028?lang=en_us&edition=fundamental","pubTime":"2026-09-01 05:24","pubTimestamp":1788211494,"startTime":"0","endTime":"0","summary":"There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/companies-like-amplia-therapeutics-asxatx-are-in-a-position-3","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-atx/amplia-therapeutics-shares/news/companies-like-amplia-therapeutics-asxatx-are-in-a-position-3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ATX.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656567235","title":"Amplia Therapeutics Signs Trial Collaboration with Lilly for Narmafotinib-Olomorasib NSCLC Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2656567235","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656567235?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:45","pubTimestamp":1785847551,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics signs trial collaboration with Lilly for narmafotinib-olomorasib NSCLC studyAmplia entered a clinical trial collaboration and supply agreement with Eli Lilly to test narmafotinib w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL4rKcYG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","BK4112","SG9999014039.USD","BK4588","LU2210149790.SGD","BK7067","BCDF","IE00B3QW5Z07.USD","ATX.AU","IE00BN0W2W23.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656794556","title":"Amplia Signs Collaboration Agreement with Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12c Inhibitor, Olomorasib, in Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656794556","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656794556?lang=en_us&edition=fundamental","pubTime":"2026-08-04 20:45","pubTimestamp":1785847500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA96JSHB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","ATX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656588824","title":"Amplia Therapeutics to Evaluate Combination Therapy for Non-Small Cell Lung Cancer in Collaboration With Eli Lilly","url":"https://stock-news.laohu8.com/highlight/detail?id=2656588824","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656588824?lang=en_us&edition=fundamental","pubTime":"2026-08-04 07:23","pubTimestamp":1785799418,"startTime":"0","endTime":"0","summary":"Amplia Therapeutics  struck a collaboration and supply agreement with US-listed pharmaceutical giant Eli Lilly to evaluate an investigational drug combination as a second-line treatment for patients with advanced-stage non-small cell lung cancer, according to a Tuesday filing with the Australian bourse.As part of the deal, a phase 1b/2b clinical trial will assess the safety and efficacy of Amplia's narmafotinib in combination with Eli Lilly's olomorasib, per the filing.Amplia will conduct the trial, which is planned to launch late this year, at sites in Australia and the US. The companies will collaborate to finalize the clinical study protocol and other associated documents.The study extends narmafotinib's clinical development from pancreatic cancer into non-small cell lung cancer, for which the market is currently valued at about $31 billion, Amplia said. It added that narmafotinib showed a range of \"compelling efficacy signals\" across responses and survival in a previous study, with","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1093756325.SGD","FTXH","LU0820562030.AUD","TMED","LU0198837287.USD","LU1720051108.HKD","LU0432979614.USD","IE00B4JS1V06.HKD","LU0238689110.USD","LU2417539215.USD","LU0353189763.USD","IE00BFSS8Q28.SGD","AGNG","LU1023059063.AUD","LU1868837300.USD","LU0354030438.USD","LU0289739699.SGD","LU2456880835.USD","LU2756315318.SGD","LU0114720955.EUR","LU0058720904.USD","IE00B2B36J28.USD","LU0345770308.USD","LU2361044949.HKD","LU0345770993.USD","LU0158827781.USD","MEDI","LU0823434740.USD","LU2746668461.USD","LU0234572021.USD","IE00BJJMRX11.SGD","LU1917777945.USD","LU0882574139.USD","LU2361045086.USD","LU0122379950.USD","GDOC","LU0158827948.USD","LU0708995401.HKD","LU0210536198.USD","LU0787776722.HKD","LU1868836914.USD","LU2063271972.USD","SG9999015986.USD","LU1720051017.SGD","LU0889565916.HKD","IE00BWXC8680.SGD","LU1868837136.USD","LU1974910355.USD","LU2213496289.HKD","LU1057294990.SGD","LU1069344957.HKD","LU1804176565.USD","LU1988902786.USD","LU2265009873.SGD","IE00BJLML261.HKD","MEDX","SG9999017495.SGD","LU2461242641.AUD","LU0256863811.USD","IE00B1BXHZ80.USD","SG9999015945.SGD","LU1267930730.SGD","LU0203202063.USD","BK4534","IE00B7KXQ091.USD","LU1145028129.USD","LU2750360641.GBP","LU0106261372.USD","SG9999014906.USD","IE00BJJMRZ35.SGD","SGXZ81514606.USD","LU2896262040.SGD","LU1868836757.USD","LU0672654240.SGD","VHT","LU1366192091.USD","LU0316494557.USD","BK4599","JDOC","LU2471134879.HKD","OZEM","LU2111349929.HKD","BK4533","LU0320765992.SGD","IE0005OL40V9.USD","IE00BK4W5M84.HKD","LU2271345857.HKD","LU1064131342.USD","IE0001KFT4U8.USD","LU2023250330.USD","LU0786609619.USD","LU2468319806.SGD","XLV","LU2237443978.SGD","PPH","SG9999015952.SGD","LU0820561818.USD","LU1093756168.USD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","CANC","IE00BKDWB100.SGD","LLII","LU2023251221.USD","LU2168564149.EUR","LU0640476718.USD","LU2462591350.SGD","LU0061475181.USD","LU0097036916.USD","FHLC","SG9999014898.SGD","LU0320765059.SGD","LU1814569148.SGD","LU2168564222.USD","SGXZ31699556.SGD","LU0943347566.SGD","BK4007","LU0079474960.USD","LU2552382215.SGD","WDNA","LU2552382058.USD","LU2236285917.USD","LU2756315664.SGD","IE00BKPKM429.USD","GB00BDT5M118.USD","LU0964807845.USD","LU2237438978.USD","LU2089284900.SGD","LU0417517546.SGD","SG9999015978.USD","LU1979441026.SGD","LU1868836591.USD","LU2106854487.HKD","LU2168564065.EUR","LU2491049909.HKD","ELIL","LU0174119429.USD","LU0323591593.USD","LU1323610961.USD","LU2360106947.USD","LU2028103732.USD","LLY","LU2357305700.SGD","LLYZ","LU2491050071.SGD","LU1989771016.USD","PJP","LU1291159041.SGD","LU2471134796.USD","IE0004445239.USD","LLYX","LU2491050154.USD","LU2168564495.EUR","LU2211815571.USD","LU0133085943.USD","LU0456855351.SGD","IE00BJJMRY28.SGD","CURE","LU2552382132.HKD","LU2750360997.AUD","IE00B775H168.HKD","SGXZ51526630.SGD","MHIP","LU0203201768.USD","LU1548497426.USD","LU2237443549.SGD","SGXZ57979304.SGD","ELIS","LU2089283258.USD","LU2324357040.USD","SG9999018857.SGD","IE00BFSS7M15.SGD","LU0006306889.USD","TRUH","LU2462157665.USD","SG9999001176.SGD","LU1232071149.USD","LU2089984988.USD","LU2361044865.SGD","SG9999018865.SGD","LU0354030511.USD","ILDR","LU1551013342.USD","BK7067","SG9999001176.USD","LU0109391861.USD","SGXZ99366536.SGD","LU1551013425.SGD","LU0882574055.USD","LU1712237335.SGD","LU2264538146.SGD","BK4588","LU1280957306.USD","LU1629891620.HKD","LU2237443465.HKD","LU1127390331.HKD","IE0002141913.USD","LU1061106388.HKD","LU2471134523.USD","IE00B1XK9C88.USD","BK4516","LU2087625088.SGD","LU2112291526.USD","HRTS","SG9999014880.SGD","IYH","LU0683600562.USD","LU2237443895.HKD","THNR","LU2602419157.SGD","LU0466842654.USD","LU0471298777.SGD","LU0385154629.USD","IE00BN29S564.USD","IXJ","LU2168563687.JPY","LU1983299246.USD","LU0256863902.USD","LU2023250504.SGD","LU1623119135.USD","LU2471134952.CNY","ATX.AU","RXL","LU0823416689.USD","LU2746668974.SGD","LU0225283273.USD","LU0109394709.USD","LU0266013472.USD","BK4581","SG9999013999.USD","IE0004445015.USD","LU2237443622.USD","LU0471298694.HKD","LU0094547139.USD","SG9999014914.USD","LU0689472784.USD","LU0353189680.USD","IE0009355771.USD","BK4585","LU1035775433.USD","IE00BFTCPJ56.SGD","LU0820561909.HKD","LU0823434583.USD","LU2237443382.USD","IE00BK4W5L77.USD","IHE","LU0096364046.USD","LU2108987350.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":10,"pageCount":1,"totalSize":38,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATX.AU\",params:#limit:6,delay:true,,,undefined,":[]}}